Search

Your search keyword '"Pineda-Solis, Karen"' showing total 25 results
Start Over Author "Pineda-Solis, Karen" Publication Year Range Last 10 years
25 results on '"Pineda-Solis, Karen"'

2. The Rochester Protocol for Living Donor Liver Transplantation of Unresectable Colorectal Liver Metastasis: A 5-Year Report on Selection, Approval, and Outcomes

Author

Byrne, Matthew M., Chávez-Villa, Mariana, Ruffolo, Luis I., Loria, Anthony, Endo, Yutaka, Niewiemski, Amber, Jimenez-Soto, Cristina, Melaragno, Jennifer I., Ramaraju, Gopal A., Farooq, Priya D., Dunne, Richard F., Pineda-Solis, Karen, Nair, Amit, Orloff, Mark, Tomiyama, Koji, and Hernandez-Alejandro, Roberto

Published
2024
Full Text
View/download PDF

16. Robotic Assisted Transplant Nephrectomy: Case Series and Training Model for Improving Adoption

Author

McCabe, Michael, primary, Osinski, Thomas, additional, Kashyap, Randeep, additional, Taylor, Jeremy, additional, Schuler, Nathan, additional, Shepard, Lauren, additional, Ghazi, Ahmed, additional, Helbig, Katie, additional, Dokus, M. Katherine, additional, Nair, Amit, additional, Pineda-Solis, Karen, additional, Orloff, Mark, additional, and Wu, Guan, additional

Published
2023
Full Text
View/download PDF

19. Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases

Author

Hernandez-Alejandro, Roberto, primary, Ruffolo, Luis I., additional, Sasaki, Kazunari, additional, Tomiyama, Koji, additional, Orloff, Mark S., additional, Pineda-Solis, Karen, additional, Nair, Amit, additional, Errigo, Jennie, additional, Dokus, M. Katherine, additional, Cattral, Mark, additional, McGilvray, Ian D., additional, Ghanekar, Anand, additional, Gallinger, Steven, additional, Selzner, Nazia, additional, Claasen, Marco P. A. W., additional, Burkes, Ron, additional, Hashimoto, Koji, additional, Fujiki, Masato, additional, Quintini, Cristiano, additional, Estfan, Bassam N., additional, Kwon, Choon Hyuck David, additional, Menon, K. V. Narayanan, additional, Aucejo, Federico, additional, and Sapisochin, Gonzalo, additional

Published
2022
Full Text
View/download PDF

20. Recipient and Donor Outcomes after Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases

Author

Hernandez-Alejandro, Roberto, Ruffolo, Luis I., Sasaki, Kazunari, Tomiyama, Koji, Orloff, Mark S., Pineda-Solis, Karen, Nair, Amit, Errigo, Jennie, Dokus, M. Katherine, Cattral, Mark, McGilvray, Ian D., Ghanekar, Anand, Gallinger, Steven, Selzner, Nazia, Claasen, Marco P.A.W., Burkes, Ron, Hashimoto, Koji, Fujiki, Masato, Quintini, Cristiano, Estfan, Bassam N., Kwon, Choon Hyuck David, Menon, K. V.Narayanan, Aucejo, Federico, Sapisochin, Gonzalo, Hernandez-Alejandro, Roberto, Ruffolo, Luis I., Sasaki, Kazunari, Tomiyama, Koji, Orloff, Mark S., Pineda-Solis, Karen, Nair, Amit, Errigo, Jennie, Dokus, M. Katherine, Cattral, Mark, McGilvray, Ian D., Ghanekar, Anand, Gallinger, Steven, Selzner, Nazia, Claasen, Marco P.A.W., Burkes, Ron, Hashimoto, Koji, Fujiki, Masato, Quintini, Cristiano, Estfan, Bassam N., Kwon, Choon Hyuck David, Menon, K. V.Narayanan, Aucejo, Federico, and Sapisochin, Gonzalo

Abstract

Importance: Colorectal cancer is a leading cause of cancer-related death, and nearly 70% of patients with this cancer have unresectable colorectal cancer liver metastases (CRLMs). Compared with chemotherapy, liver transplant has been reported to improve survival in patients with CRLMs, but in North America, liver allograft shortages make the use of deceased-donor allografts for this indication problematic. Objective: To examine survival outcomes of living-donor liver transplant (LDLT) for unresectable, liver-confined CRLMs. Design, Setting, and Participants: This prospective cohort study included patients at 3 North American liver transplant centers with established LDLT programs, 2 in the US and 1 in Canada. Patients with liver-confined, unresectable CRLMs who had demonstrated sustained disease control on oncologic therapy met the inclusion criteria for LDLT. Patients included in this study underwent an LDLT between July 2017 and October 2020 and were followed up until May 1, 2021. Exposures: Living-donor liver transplant. Main Outcomes and Measures: Perioperative morbidity and mortality of treated patients and donors, assessed by univariate statistics, and 1.5-year Kaplan-Meier estimates of recurrence-free and overall survival for transplant recipients. Results: Of 91 evaluated patients, 10 (11%) underwent LDLT (6 [60%] male; median age, 45 years [range, 35-58 years]). Among the 10 living donors, 7 (70%) were male, and the median age was 40.5 years (range, 27-50 years). Kaplan-Meier estimates for recurrence-free and overall survival at 1.5 years after LDLT were 62% and 100%, respectively. Perioperative morbidity for both donors and recipients was consistent with established standards (Clavien-Dindo complications among recipients: 3 [10%] had none, 3 [30%] had grade II, and 4 [40%] had grade III; donors: 5 [50%] had none, 4 [40%] had grade I, and 1 had grade III). Conclusions and Relevance: This study's findings of recurrence-free and overall survival rates sugg

Published
2022

23. MP32-07 WARM PERFUSION OF CARBON MONOXIDE RELEASING MOLECULE 401 REDUCES INFLAMMATION AND DAMAGE IN PRECLINICAL DONATION AFTER CARDIAC DEATH KIDNEY TRANSPLANTATION MODEL

Author

Bhattacharjee, Rabindra, primary, Richard Mohamed, Mahms, additional, Saha, Manu, additional, Pineda Solis, Karen, additional, Mayer, Richard, additional, Barrett, Peter, additional, AlHasan, Ibrahim, additional, Aboalsamh, Ghaleb, additional, Cepinskas, Gediminas, additional, and Luke, Patrick, additional

Published
2016
Full Text
View/download PDF

25. Wading through the noise of "multi-omics" to identify prognostic biomarkers in hepatocellular carcinoma.

Author

Pineda-Solis K and McAlister V

Abstract

Multi-omics, the molecular analysis of genes, transcriptional RNA and proteins, allows researchers document the mechanism of action of a target gene. However multi-omics may result in an avalanche of information when used to screen a population. It is very difficult to discern a pattern or signal related to a disease or its progression. Differential multi-omics exploits our ability to see differences between subjects who are similar in all respects except for the outcome being tested. Twin studies are an example of this. Miao and colleagues compared two patients who had diverse outcomes following treatment of multi-focal hepatocellular carcinoma (HCC) to identify seven candidates as the responsible genes. In a larger cohort of patients with HCC they narrowed the field down to a single target down. By looking at progression of HCC, they isolated TTK, a protein kinase which disrupts the interaction of the tumour suppressor p53 with the oncogene MDM2. TTK-high tumours recurred 3 times faster than TTK-low tumours.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results